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ABSTRACT  41 
We have compared the HIV-1-specific cellular and humoral immune responses elicited 42 
in rhesus macaques immunized with two poxvirus vectors (NYVAC and ALVAC) 43 
expressing the same HIV-1 antigens from clade C, Env gp140 as a trimeric cell released 44 
protein and Gag-Pol-Nef as Gag-induced virus-like particles (VLPs) (referred as 45 
NYVAC-C and ALVAC-C). The immunization protocol consisted of two doses of the 46 
corresponding poxvirus vector plus two doses of a combination of the poxvirus vector 47 
and a purified HIV-1 gp120 protein from clade C. This immunogenicity profile was also 48 
compared to that elicited by vaccine regimens consisting of two doses of the ALVAC 49 
vector expressing HIV-1 antigens from clades B/E (ALVAC-vCP1521) plus two doses 50 
of a combination of ALVAC-vCP1521 and HIV-1 gp120 protein from clades B/E 51 
(similar to the RV144 trial regimen) or clade C. The results showed that immunization 52 
of macaques with NYVAC-C stimulated at different times more potent HIV-1-specific 53 
CD4+ T-cell responses and induced a trend toward higher magnitude of HIV-1-specific 54 
CD8+ T-cell immune responses than ALVAC-C. Furthermore, NYVAC-C induced a 55 
trend toward higher levels of binding IgG antibodies against clade C HIV-1 gp140, 56 
gp120 or MuLV gp70-scaffolded V1/V2 and toward best cross-clade binding IgG 57 
responses against HIV-1 gp140 from clades A, B and group M consensus, compared to 58 
ALVAC-C. Of the linear binding IgG responses most were directed against the V3 loop 59 
in all immunization groups. Additionally, NYVAC-C and ALVAC-C also induced 60 
similar levels of HIV-1 neutralizing antibodies and antibody-dependent cellular 61 
cytotoxicity (ADCC) responses. Interestingly, binding IgA antibodies against HIV-1 62 
gp120 or MuLV gp70-scaffolded V1/V2 were absent or very low in all immunization 63 
groups. Overall, these results provide a comprehensive survey of the immunogenicity of 64 
NYVAC versus ALVAC expressing HIV-1 antigens in non-human primates and 65 
4 
 
indicate that NYVAC may represent an alternative candidate to ALVAC in the 66 
development of a future HIV-1 vaccine. 67 
 68 
IMPORTANCE 69 
The finding of a safe and effective HIV/AIDS vaccine immunogen is one of the main 70 
research priorities. Here, we have generated two poxvirus-based HIV vaccine 71 
candidates (NYVAC and ALVAC vectors) expressing the same clade C HIV-1 antigens 72 
in separate vectors  and tested in non-human primates their immunogenicity profile. The 73 
results showed that immunization with NYVAC-C induced a trend toward higher HIV-74 
1-specific cellular and humoral immune responses than those elicited by ALVAC-C, 75 
indicating that this new NYVAC vector could be considered a novel optimized 76 
HIV/AIDS vaccine candidate for human clinical trials. 77 
78 
5 
 
INTRODUCTION 79 
The development of a safe and effective HIV/AIDS vaccine that could prevent HIV-1 80 
infection by inducing effective cellular and humoral immune responses is a key research 81 
priority. The Thai phase III HIV-1 vaccine clinical trial (RV144) tested a prime/boost 82 
combination of a recombinant poxvirus vector, ALVAC vCP1521 expressing HIV-1 83 
antigens from clades B and E, combined with bivalent HIV-1 gp120 proteins from 84 
clades B and CRF01_AE, showing a 31.2% protection against HIV-1 infection in 85 
humans (1). This modest efficacy highlighted the poxvirus vector as an important player 86 
in these responses, promoting the generation and characterization of new optimized 87 
attenuated poxvirus vectors with improved immunogenicity as future HIV-1 vaccine 88 
candidates (2-5). 89 
Among poxviruses, the highly attenuated vaccinia virus strain NYVAC (6) is a 90 
promising vector that has been broadly used in preclinical and clinical trials as a 91 
prototype vaccine against HIV-1, inducing a good immunogenicity profile in different 92 
animal models (mice and non-human primates) and in humans (2, 7). In particular, 93 
recombinant NYVAC vectors expressing HIV-1 Env, Gag, Pol and Nef antigens from 94 
clades B or C elicited strong, broad and polyfunctional T-cell immune responses in 95 
mice, non-human primates and humans, together with some levels of humoral responses 96 
against HIV-1 gp120 (8-23). An additional feature is that the current NYVAC vectors 97 
preferentially triggered CD4+ T-cell responses (13, 14, 24, 25) in both humans and 98 
macaques, inferring immunologically the recruitment of stronger B-cell responses than 99 
ALVAC-based vectors. In an effort to enhance the magnitude and scope of T- and B-100 
cell responses to HIV-1 antigens delivered by a poxvirus vector, we have recently 101 
reported the characterization of two novel attenuated NYVAC vectors expressing HIV-1 102 
clade C trimeric soluble gp140 or Gag-Pol-Nef as a polyprotein processed into Gag-103 
6 
 
derived VLPs, which triggered specific innate responses in human cells and elicited in 104 
mice polyfunctional Env-specific CD4+ and Gag-specific CD8+ T-cell responses, 105 
together with antibody responses against HIV-1 gp140 and p17/p24 (26). Furthermore, 106 
DNA plasmids producing these improved immunogens lead to higher expression levels 107 
and enhanced immunogenicity after DNA vaccination in mice (27) and after DNA 108 
prime/NYVAC boost in non-human primates (Asbach B et al, submitted).  109 
A comparison of the immunogenicity elicited by different poxvirus vectors expressing 110 
the same HIV-1 antigens is of particular importance, as it may provide details of the 111 
best-in-class vector to be advanced for future phase III human trials. To this end, in a 112 
pre-clinical study in rhesus macaques, we have evaluated head to head, the HIV-1-113 
specific cellular and humoral immune responses elicited by NYVAC and ALVAC pox-114 
vectors, expressing identical clade C HIV-1 inserts, Env gp140 as a trimeric soluble 115 
protein and Gag-Pol-Nef as a polyprotein processed into Gag-derived VLPs (referred as 116 
NYVAC-C and ALVAC-C). NYVAC-C and ALVAC-C were administered using an 117 
immunization protocol consisting of two priming doses of the corresponding 118 
recombinant poxvirus vectors boosted with two doses of a combination of the poxvirus 119 
vector and HIV-1 gp120 protein from clade C. Moreover, we also compared the 120 
immunogenicity elicited by these two vaccine candidates with the one induced by the 121 
same ALVAC vector used in the RV144 phase III clinical trial (ALVAC-vCP1251, 122 
expressing HIV-1 antigens from clades B and E), and administered following two 123 
priming doses of ALVAC-vCP1251 plus two boosts combining ALVAC-vCP1251 and 124 
HIV-1 gp120 protein from clades C or B/E. The results showed that while the two 125 
vectors triggered both T- and B-cell immune responses, NYVAC-C was more 126 
immunogenic than ALVAC-C, inducing at different times higher HIV-1-specific CD4+ 127 
T-cell responses, with a trend toward higher magnitude of HIV-1-specific CD8+ T-cell 128 
7 
 
immune responses and a consistent trend toward higher antibody responses against 129 
HIV-1 gp140, gp120 or MuLV gp70-scaffolded V1/V2. These results support the 130 
further clinical development of NYVAC-C as a component HIV/AIDS vaccine 131 
candidate. 132 
 133 
MATERIALS AND METHODS 134 
Recombinant NYVAC and ALVAC vectors expressing HIV-1 antigens  135 
The recombinant NYVAC-C consists of two NYVAC vectors that express different 136 
clade C HIV-1 antigens under the same synthetic early/late poxvirus promoter (28): one 137 
(NYVAC-gp140) expressing Env gp140 from strain 96ZM651 and one (NYVAC-Gag-138 
Pol-Nef) expressing Gag from strain 96ZM651 and Pol/Nef from strain CN54, and their 139 
generation and virological characteristics have been previously described (26). For 140 
head-to-head comparison purposes, the recombinant ALVAC-C was generated and 141 
consists of a combination of two ALVAC vectors expressing the same clade C HIV-1 142 
antigens present in NYVAC-C (ALVAC-gp140 and ALVAC-Gag-Pol-Nef), and was 143 
generated by Sanofi Pasteur. Briefly, Env gp140 or Gag-Pol-Nef HIV-1 genes were 144 
inserted into the ALVAC C6 locus under the control of the synthetic early/late poxvirus 145 
promoter (28). The ALVAC backbone of ALVAC–C vectors is the same that was used 146 
to generate the recombinant ALVAC-vCP1521 vector and the HIV-1 antigens were 147 
inserted in the same locus (C6). ALVAC product is licensed for veterinary use under the 148 
name KANAPOX®. For the isolation of viral recombinants, 3 x 106 primary chicken 149 
embryo ﬁbroblast (CEF) cells were first infected with ALVAC parental virus at a 150 
multiplicity of infection (MOI) of 10 plaque forming units (PFU)/cell and transfected 1 151 
h later with 8 µg of linearized DNA (containing Env gp140 or Gag-Pol-Nef) using 152 
lipofectamine 2000CD (Life Technologies), according to the manufacturer´s 153 
8 
 
recommendations. After 24 h of incubation, the cells were harvested in 1 ml of 2% 154 
FBS-DMEM, sonicated and used for recombinant virus screening. Recombinant 155 
ALVAC viruses containing gp140 or Gag-Pol-Nef genes were screened and purified by 156 
plaque purification on primary CEF cells. After 4 consecutive rounds of plaque 157 
purification, positive plaques were isolated and confirmed to be positive to the gp140 or 158 
GPN DNA probe and negative to the ALVAC C6 open reading frame probe. The 159 
resulting ALVAC-gp140 and ALVAC-Gag-Pol-Nef recombinant viruses were 160 
expanded in primary CEF cells and the crude preparations obtained were used for the 161 
propagation of both viruses in large cultures of CEF cells followed by virus puriﬁcation 162 
through two 36% (wt/vol) sucrose cushions and virus titrated. For simplicity of 163 
terminology, we subsequently refer to the combined mixed inoculation of NYVAC-164 
gp140 + NYVAC-Gag-Pol-Nef as NYVAC-C and ALVAC-gp140 + ALVAC-Gag-Pol-165 
Nef is labeled as ALVAC-C. The recombinant ALVAC-vCP1521 expresses HIV-1 166 
gp120 from clade E, transmembrane gp41 from clade B and Gag/Pro from clade B, and 167 
was used previously in the RV144 phase III clinical trial (1). 168 
 169 
HIV-1 proteins  170 
In the immunizations performed in this study, two different HIV-1 gp120 proteins from 171 
clades C or B/E were used. Bivalent gp120 protein contains a mixture of TV1 gp120 172 
and 1086 gp120, both from clade C. These proteins were expressed from stably 173 
transfected Chinese hamster ovary (CHO) cell lines, purified and characterized as 174 
previously described (29). Bivalent AIDSVAX gp120 protein contains a mixture of 175 
gp120 from clades B and CRF01_AE was used previously in the RV144 phase III 176 
clinical trial (1), and was provided by Global Solutions for Infectious Diseases. 177 
 178 
9 
 
Non-human primates 179 
Animals used in this study (designated AUP513) were outbred adult male Indian rhesus 180 
macaques (Macaca mulatta) which were housed and handled in accordance with the 181 
standards of the Association for the Assessment and Accreditation of Laboratory 182 
Animal Care International (AAALAC International). This study protocol was approved 183 
by the Institutional Animal Care and Use Committee of Advanced BioScience 184 
Laboratories in accordance with international guidelines. The age of the animals ranged 185 
between 2.5 and 2.9 years, with a mean of 2.6 years and the weight range was between 186 
3.1 to 5.7 kg, with a mean of 3.8 kg. All rhesus macaques were negative for 187 
tuberculosis, simian retrovirus (SRV), simian T-cell leukemia virus (STLV-1), 188 
herpesvirus B, simian immunodeficiency virus (SIV), measles and poxvirus 189 
immunogens prior to the study, and have also negative fecal culture for salmonella, 190 
shigella, campylobacter and yersinia. Furthermore animals were immunologically naïve 191 
for the vaccine components. 192 
 193 
Immunization schedule 194 
Four immunizations groups of eight rhesus macaques were included in this study 195 
protocol (designated AUP513). Group 1 consisted of two immunizations with NYVAC-196 
C (weeks 0 and 4) boosted with two immunizations of NYVAC-C plus bivalent gp120 197 
proteins from clade C (TV1 + 1086 gp120) (weeks 12 and 24). Group 2 consisted of 198 
two immunizations with ALVAC-C (weeks 0 and 4) boosted with two immunizations 199 
of ALVAC-C plus bivalent gp120 proteins from clade C (TV1 + 1086 gp120) (weeks 200 
12 and 24). Group 3 consisted of two immunizations with ALVAC-vCP1521 (weeks 0 201 
and 4) boosted with two immunizations of ALVAC-vCP1521 plus bivalent gp120 202 
proteins from clade C (TV1 + 1086 gp120) (weeks 12 and 24). Group 4 consisted of 203 
10 
 
two immunizations with ALVAC-vCP1521 (weeks 0 and 4) boosted with two 204 
immunizations of ALVAC-vCP1521 plus bivalent gp120 from clades B/E (AIDSVAX 205 
gp120) (weeks 12 and 24). The pox-vector priming immunization was carried out at 0 206 
and 4 weeks with the corresponding poxvirus vectors (NYVAC-C, ALVAC-C or 207 
ALVAC-vCP1251) and boosted at weeks 12 and 24 with the combination of poxvirus 208 
vector plus HIV-1 gp120 proteins (from clades C or B/E) (as depicted in Fig. 1A and 209 
1B). All immunizations for the poxvirus vectors and proteins were given 210 
intramuscularly (i.m) in the deltoid muscle in the upper right arm for the poxvirus 211 
vectors and in the opposite site, upper left arm for the proteins. A dose of 1 x 108 PFU 212 
of each recombinant poxvirus vector (NYVAC-C, ALVAC-C or ALVAC-vCP1521; 2 x 213 
108 PFU of total virus in 1.0 ml) and 50 µg of each HIV-1 gp120 protein (from clades C 214 
with adjuvant MF59 or B/E with adjuvant Alum; 100 µg of total protein in 1.0 ml) was 215 
used in each immunization. It should be pointed out that group 3 received the identical 216 
RV144 immunogen prime (ALVAC-vCP1521), but was boosted with ALVAC-217 
vCP1521 and with the same bivalent clade C gp120 proteins as in groups 1 and 2. 218 
Moreover, as an immunological benchmark the immunization regimen used in group 4 219 
was essentially homologous to the one used in the RV144 phase III clinical trial (1) 220 
differing in the vaccine dose [RV144 used a lower dose of ALVAC-vCP1521 (>106 cell 221 
culture infectious dose 50%) and higher dose of AIDSVAX B/E gp120 (300 µg of each 222 
protein)]. At weeks 0, 6, 14 and 26 (at the beginning of the study and two weeks after 223 
the second, third and fourth immunizations, respectively), peripheral blood 224 
mononuclear cells (PBMCs) and serum samples were obtained from each immunized 225 
animal and HIV-1-specific T-cellular and humoral immune responses were analyzed 226 
(Fig. 1B). Blood samples were processed following current procedures (30).  227 
 228 
11 
 
Intracellular cytokine staining (ICS) assay  229 
The HIV-1-specific CD4+ and CD8+ T-cell immune responses induced at weeks 6, 14 230 
and 26 were analyzed by polychromatic ICS from PBMCs obtained from each 231 
immunized rhesus monkey, as previously described (30). In short, cryopreserved 232 
PBMCs were thawed and rested overnight in R10 [RPMI 1640 (BioWhittaker, 233 
Walkersville, MD), 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin G, 100 μg/ml 234 
streptomycin] with 50 U/ml Benzonase (Novagen, Madison, WI) in a 37ºC/5% CO2 235 
incubator. The following morning, cells were stimulated with the corresponding HIV-1 236 
Env, Gag, Pol and Nef peptide pools (2 μg/ml) in the presence of GolgiPlug (10 μg/ml; 237 
BD Biosciences, San Jose, California) for 6 h. Negative controls received an equal 238 
concentration of DMSO instead of peptides. Subsequently, ICS was performed as 239 
described (30). The following monoclonal antibodies were used: CD4-BV421 (clone 240 
OKT4; BioLegend), CD8-BV570 (clone RPA-T8; BioLegend), CD69-ECD (clone 241 
TP1.55.3; Beckman Coulter), CD3-Cy7APC (clone SP34.2; BD Biosciences), IFN-γ-242 
APC (clone B27; BD Biosciences), IL-2-PE (clone MQ1-17H12; BD Biosciences) and 243 
TNF-α-FITC (clone Mab11; BD Biosciences). Aqua LIVE/DEAD kit (Invitrogen, 244 
Carlsbad, CA) was used to exclude dead cells. All antibodies were previously titrated to 245 
determine the optimal concentration. Samples were acquired on an LSR II flow 246 
cytometer and analyzed using FlowJo version 9.8 (Treestar, Inc., Ashland, OR). 247 
 248 
Peptides  249 
Overlapping peptides (15-mers with 11 amino acids overlapping) spanning the Env, 250 
Gag, Pol and Nef HIV-1 clade C regions were matched to the inserts expressed by 251 
NYVAC-C and ALVAC-C. Peptides used in the ICS were grouped in nine peptide 252 
12 
 
pools (Env-1, Env-2, Env-3, Pol-1, Pol-2, Gag-1, Gag/Pol, Gag-2/Pol and Nef), with 253 
about 60 peptides per pool. 254 
 255 
HIV-1-specific binding antibody assay 256 
HIV-1-specific binding antibodies were measured by Binding Antibody Multiplex 257 
Assay (BAMA) for total IgG and IgA antibodies in sera from each immunized rhesus 258 
monkey at weeks 0, 6, 14 and 26, as previously described (31, 32). Antigens used to 259 
analyze the total IgG or IgA binding antibodies included multiple HIV-1 clades: clade C 260 
gp120 TV1 and clade C gp120 1086 (provided by Novartis Vaccines), recombinant 261 
gp140 consensus from various subtypes [clade A 00MSA4076 gp140 (gp140. a1Con), 262 
clade B JRFL gp140 (gp140. bCon), clade C gp140 (gp140. cCon) and group M 263 
consensus (gp140. sCon)], murine leukemia virus (MuLV) gp70-scaffolded V1V2 264 
(from clade C) and 1086 V1/V2 tags [all provided by Drs. H.-X. Liao and B. F. Haynes, 265 
Duke University, as previously described (33)]. Different plasma serial dilutions were 266 
made and results are expressed as mean fluorescent intensity (MFI) and titer [The area 267 
under curve (AUC)]. Furthermore, rectal mucosal IgG binding responses were measured 268 
and the specific activity was calculated by dividing the antibody titer by the total IgG 269 
concentration, as previously described (34). Positivity criteria were values 3-fold over 270 
the baseline visit and the cutoff was established using serum-negative samples. All 271 
assays were run under Good Clinical Laboratory Practices (GCLP)-compliant 272 
conditions. 273 
 274 
Linear peptide microarray assay 275 
Serum from a subset of immunized animals with strong binding IgG antibodies were 276 
selected to further evaluate linear epitope specificities by linear peptide microarray, 277 
13 
 
using an Env peptide library containing 15-mer peptides, overlapping by 12 amino 278 
acids, against HIV-1 Env gp160 of consensus clades A, B, C, D, group M, CRF01 and 279 
CRF02, as previously described (35, 36).  280 
 281 
Antibody-dependent cellular cytotoxicity (ADCC) assay  282 
ADCC activity was detected according to the ADCC-GranToxiLux (GTL) procedure, as 283 
previously described (37, 38). The results of the GTL assay were considered positive if 284 
% Granzyme B activity after background subtraction was ≥8% for the infected target 285 
cells as determined during the standardization of our assay (39). The log10 titer of the 286 
ADCC antibodies present in the plasma was calculated by interpolating the log10 287 
reciprocal of the last plasma dilution that yielded positive % Granzyme B activity 288 
(≥8%). The GTL-ADCC assay was performed under GCLP-compliant guidelines. 289 
 290 
Neutralizing antibodies against HIV-1   291 
Neutralizing antibodies against HIV-1 were measured in TZM-bl cells, as previously 292 
described (40). Briefly, a pre-titrated dose of different HIV-1 virus (clade B tier 1 HIV-293 
1 strain MN.3, clade C tier 1 HIV-1 strain MW965.26 and clade CRF01_AE tier 1 HIV-294 
1 strain TH023.6) was incubated with serial 3-fold dilutions of test sample in duplicate 295 
in a total volume of 150 µl for 1 h at 37ºC in 96-well flat-bottom culture plates. Freshly 296 
trypsinized cells (10,000 cells in 100 µl of growth medium containing 75 µg/ml DEAE 297 
dextran) were added to each well. One set of control wells received cells plus virus 298 
(virus control) and another set received cells only (background control). After 48 h of 299 
incubation, 100 µl of cells was transferred to a 96-well black solid plate (Costar) for 300 
measurements of luminescence using the Britelite Luminescence Reporter Gene Assay 301 
System (PerkinElmer Life Sciences). Neutralization titers are the serum dilution at 302 
14 
 
which relative luminescence units (RLU) were reduced by 50% compared to virus 303 
control wells after subtraction of background RLUs in cell control wells. Assay stocks 304 
of molecularly cloned Env-pseudotyped viruses were prepared by transfection in 305 
293T/17 cells (American Type Culture Collection) and titrated in TZM-bl cells as 306 
previously described (40). Additional information on the assay and all supporting 307 
protocols may be found at: http://www.hiv.lanl.gov/content/nab-reference-308 
strains/html/home.htm. The assay was done under GCLP-compliant conditions. 309 
 310 
Statistical procedures 311 
The Wilcoxon Rank Sum test (when comparing two groups) and the Kruskal Wallis test 312 
(when comparing more than two groups) were used at each time point to test the null 313 
hypothesis that the groups have the same median response. All values used for 314 
analyzing proportionate representation of responses are background-subtracted. Box 315 
plots were used to summarize the distribution of various immune responses, where the 316 
mid-line of the box indicates the median, and the ends of the box denote the 25th and 317 
75th percentiles, with whiskers extended to the extreme data points that are no more 318 
than 1.5 times the interquartile range (IQR) or, if no values meet this criterion, to the 319 
data extremes. When there are both positive and negative responses, values showed in 320 
the box plots refer to the positive responses. 321 
 322 
RESULTS 323 
Immunogenicity in non-human primates immunized with NYVAC and ALVAC 324 
vectors 325 
The recombinant poxvirus vector ALVAC expressing HIV-1 antigens provided a 326 
modest level of efficacy in a phase III clinical trial in humans (1), highlighting that new 327 
15 
 
optimized poxvirus vectors are needed for improved efficacy. Thus, to develop 328 
HIV/AIDS vaccine candidates that could enhance the HIV-1-specific immunogenicity 329 
and efficacy, we have generated two new recombinant NYVAC and ALVAC poxvirus 330 
immunogens expressing in separate vectors the same Env or Gag and Pol/Nef HIV-1 331 
antigens from clade C (termed NYVAC-C and ALVAC-C, respectively). The novelty of 332 
these vectors is the expression of codon-optimized HIV-1 clade C gp140 (ZM96) as a 333 
cell released protein trimer and VLPs of Gag(ZM96) together with Pol-Nef(CN54). 334 
Here, we analyzed the HIV-1-specific T-cell and humoral immune responses induced in 335 
non-human primates by four different groups of immunized animals (8 animals/group). 336 
The immunization protocols were designed to compare head-to-head NYVAC and 337 
ALVAC poxvirus vectors expressing the same HIV-1 antigens in homologous 338 
combination and together with a HIV-1 protein component (gp120) as a booster in order 339 
to determine whether they induced distinct HIV-1-specific T-cell and antibody immune 340 
responses (Fig. 1). Figure 1A summarizes the 4 different immunization groups included 341 
in the study (see also Materials and Methods for details).  342 
As these protocols aimed to trigger both HIV-1-specific T-cell and B-cell responses, 343 
with preferential antibody responses to Env, a comprehensive analysis with 344 
standardized and validated humoral and T-cell assays was performed on serum and 345 
PBMC samples collected at weeks 0, 6, 14 and 26 (at the beginning of the study and 346 
two weeks after the second, third and fourth immunizations, respectively) (Fig. 1B).  347 
 348 
NYVAC-C elicited higher magnitude of HIV-1-specific CD4+ T-cell immune 349 
responses and a trend toward higher HIV-1-specific CD8+ T-cell immune 350 
responses than ALVAC-C  351 
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We measured the HIV-1-specific CD4+ and CD8+ T-cell immune responses elicited by 352 
the different immunization groups by multiparameter flow cytometry using ICS, after 353 
the stimulation of PBMCs obtained from each immunized rhesus monkey at weeks 6, 354 
14 and 26 with pools of peptides that spanned the HIV-1 Env, Gag, Pol and Nef clade C 355 
regions present in the inserts expressed by NYVAC-C and ALVAC-C. HIV-1-specific 356 
CD4+ and CD8+ T-cell immune responses were determined based on the frequency of 357 
IFN-γ and/or TNF-α and/or IL-2 producing cells obtained for Env, Gag, Pol and Nef 358 
peptide pools. For each T-cell subset, the response was considered positive if the value 359 
in the stimulated samples was greater than previously defined thresholds (41). 360 
Moreover, the ICS protocol used was defined previously in ICS qualification 361 
experiments (41). 362 
The magnitude of the total HIV-1-specific CD4+ T-cell immune responses induced at 363 
week 14 by the immunization group N2NP2 (C) was significantly higher than that 364 
elicited by the immunization group A2AP2 (C) (p<0.05) or by groups A2AP2 (B/E, C) 365 
and A2AP2 (B/E, AIDSVAX), respectively (Fig. 2A). At week 6 (two weeks after the 366 
two priming immunizations) there were no differences between the immunization 367 
groups. However, two weeks following the booster immunizations (week 26), 368 
immunization with N2NP2 (C) induced higher HIV-1-specific total CD4+ T-cell 369 
immune responses, but this trend was not statistically significant.  370 
On the other hand, at weeks 14 and 26 immunization with N2NP2 (C) elicited a trend 371 
toward greater magnitude of HIV-1-specific CD8+ T-cell immune responses than the 372 
other immunization groups (Fig. 2B), but the differences were not significant.  373 
Notably, comparison of cytokine responses generated by N2NP2 (C) versus A2AP2 (C) 374 
revealed that at week 14 immunization with N2NP2 (C) induced a significantly higher 375 
magnitude of HIV-1-specific CD4+ T cells producing any cytokine (IFN-γ and/or TNF-376 
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α and/or IL-2) (Fig. 3A) or only IFN-gγ (Fig. 3B), TNF-α (Fig. 3C) or IL-2 (Fig. 3D) 377 
(p<0.05). 378 
In summary, these results showed that immunization with NYVAC-C elicited higher 379 
HIV-1-specific CD4+ T-cell immune responses than ALVAC-C, and a trend toward 380 
higher CD8+ T-cell immune responses, particularly after a single booster immunization. 381 
 382 
NYVAC-C induced a trend toward increased levels of binding IgG antibodies 383 
against clade C HIV-1 gp140, gp120 and MuLV gp70-scaffolded V1/V2 proteins 384 
compared to ALVAC-C  385 
The RV144 phase III clinical trial showed that IgG antibodies against V1/V2 and V3 386 
regions of HIV-1 gp120 correlated with decreased risk of HIV-1 infection (31, 33, 42-387 
44). Thus, we analyzed the HIV-1-specific humoral immune responses elicited after 388 
immunization with N2NP2 (C), A2AP2 (C), A2AP2 (B/E, C) or A2AP2 (B/E, 389 
AIDSVAX), quantifying in individual serum samples obtained from each immunized 390 
rhesus monkey at weeks -1, 6, 14 and 26 the total binding IgG antibody levels against 391 
clade C HIV-1 gp140, gp120 and MuLV gp70-scaffolded V1/V2 proteins (Fig. 4).  392 
At week 6, immunization with N2NP2 (C) significantly enhanced the levels of binding 393 
IgG antibodies against clade C HIV-1 gp140 consensus (Fig. 4A), gp120 from isolate 394 
1086 (Fig. 4B) and gp120 from isolate TV1 (Fig. 4C), compared to immunization with 395 
A2AP2 (C), A2AP2 (B/E, C) or with A2AP2 (B/E, AIDSVAX) from which binding 396 
IgG antibodies were either rarely present or of lower magnitude. Furthermore, at week 6 397 
immunization with N2NP2 (C) elicited a higher rate of responders than any A2AP2 398 
immunization regimen (Fig. 4A to 4D). Moreover, at week 14 immunization with 399 
N2NP2 (C) significantly enhanced the levels of binding IgG antibodies against clade C 400 
HIV-1 gp140 consensus (Fig. 4A) and gp120 from isolate 1086 (Fig. 4B), compared to 401 
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immunization with A2AP2 (C), A2AP2 (B/E, C) or with A2AP2 (B/E, AIDSVAX). 402 
Additionally, at late timepoints (week 26) immunization with N2NP2 (C) slightly 403 
enhanced the levels of binding IgG antibodies against the HIV-1 gp140 consensus (Fig. 404 
4A), gp120 from isolate 1086 (Fig. 4B), gp120 from isolate TV1 (Fig. 4C) and MuLV 405 
gp70-scaffolded V1/V2 proteins (Fig. 4D), compared to immunization with any A2AP2 406 
immunization regimen, but differences were not significant.  407 
Moreover, rectal IgG binding responses against group M HIV-1 gp140 consensus (Fig. 408 
5A), gp120 from clade C isolate 1086 (Fig. 5B), gp120 from clade C isolate TV1 (Fig. 409 
5C), and MuLV gp70-scaffolded V1/V2 proteins (Fig. 5D) were also detected in all 410 
immunization groups, only at weeks 14 and 26 (Fig. 5). The rate of responders against 411 
group M and clade C HIV-1 gp140 consensus at week 26 was higher in the NYVAC-C 412 
immunization group compared to ALVAC-C (80% versus 57% for both antigens) (Fig 413 
5A and data not shown).  414 
In summary, these results showed that immunization with NYVAC-C generated a trend 415 
towards higher binding IgG antibodies against clade C HIV-1 gp140, gp120 and MuLV 416 
gp70-scaffolded V1/V2 proteins as compared to ALVAC-C. 417 
 418 
NYVAC-C induced a trend toward higher levels of cross-clade binding IgG 419 
antibodies against HIV-1 gp140 from clades A, B and group M consensus than 420 
ALVAC-C  421 
Next, we analyzed the ability of the immunizations with N2NP2 (C), A2AP2 (C), 422 
A2AP2 (B/E, C) and A2AP2 (B/E, AIDSVAX) to induce cross-clade antibodies against 423 
HIV-1 gp140, quantifying in individual serum samples obtained from each immunized 424 
rhesus monkey at weeks -1, 6, 14 and 26 the total binding IgG antibody levels against 425 
HIV-1 gp140 from clades A, B and group M consensus (Fig. 6).  426 
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Similar to the IgG binding antibody responses against clade C HIV-1 Env, at week 6 427 
animals immunized with N2NP2 (C) produced significantly enhanced levels of cross-428 
clade binding IgG antibodies against HIV-1 gp140 from clades A (Fig. 6A), B (Fig. 6B) 429 
and group M consensus (Fig. 6C) compared to immunization with A2AP2 (C) or with 430 
A2AP2 (B/E, C), where cross-clade binding IgG antibodies were either non-existent 431 
(against clade B) or of lower magnitude (against clade A and group M consensus). 432 
Furthermore, at week 6 immunization with N2NP2 (C) elicited a higher rate of 433 
responders than A2AP2 (Fig. 6A to 6D). Nonetheless, the results at late time points 434 
(week 26) showed that immunization with N2NP2 (C) and A2AP2 (C) induced similar 435 
levels of binding IgG antibodies against HIV-1 gp140 from clades A (Fig. 6A), B (Fig. 436 
6B) and group M (Fig. 6C).  437 
In summary, these results showed that during the priming phase immunization 438 
NYVAC-C induced higher levels of cross-clade binding IgG antibodies against HIV-1 439 
gp140 from clades A, B and group M consensus than ALVAC-C, and boosting with 440 
either vector plus protein induced similar levels of cross-clade binding IgG antibodies 441 
against HIV-1 gp140 from clades A, B and group M consensus. 442 
 443 
NYVAC-C and ALVAC-C induced IgG antibodies mainly directed against the V3 444 
loop  445 
The induction of plasma IgG antibodies to linear epitopes in the V2 and V3 regions of 446 
HIV-1 gp120 correlates with a reduced risk of infection in the RV144 phase III clinical 447 
trial (43). Thus, we next selected a subset of animals that developed strong binding IgG 448 
antibodies [belonging to the N2NP2 (C), A2AP2 (C) and A2AP2 (B/E, AIDSVAX) 449 
immunization groups] to evaluate linear epitope specificities by peptide microarray 450 
against Env gp160 of consensus clades A, B, C, D, group M, CRF01 and CRF02. The 451 
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 
results showed that V3-response dominated the binding response in most animals, 452 
consisting on average 41% of total gp160 binding, followed by C5 (24%) and C1-V1 453 
(11%) epitopes (Figure 7A and 7B). Other linear epitope specific responses were 454 
detected to C1.1, C1.2, C2 and V2 epitopes, but with lower magnitude binding. 455 
 456 
NYVAC-C and ALVAC-C induced similar levels of ADCC responses against HIV-457 
1 gp120  458 
It has been suggested that ADCC responses are linked with a reduced risk of infection 459 
in the RV144 phase III clinical trial (33). Moreover, antibodies with potent ADCC 460 
activity have been isolated from some RV144 vaccinees (45). Thus, we analyzed the 461 
ability of the immunizations with N2NP2 (C), A2AP2 (C), A2AP2 (B/E,C) and A2AP2 462 
(B/E, AIDSVAX) to induce ADCC responses against clade C HIV-1 gp120 from isolate 463 
TV1 in individual plasma samples obtained from each immunized rhesus monkey at 464 
weeks 0 and 26  (Fig. 8). The results showed that immunization with N2NP2 (C) and 465 
A2AP2 (C) induced similar levels of ADCC responses (Fig. 8). 466 
 467 
NYVAC-C and ALVAC-C induced similar levels of neutralizing antibodies against 468 
HIV-1 469 
Broad neutralizing antibodies are a highly desired feature of an HIV-1 vaccine response 470 
(46). We analyzed the neutralizing antibody responses to HIV-1 induced in macaques 471 
immunized with N2NP2 (C), A2AP2 (C), A2AP2 (B/E,C) and A2AP2 (B/E, 472 
AIDSVAX) in individual serum samples obtained from each immunized rhesus monkey 473 
at weeks -1, 6, 14 and 26 (Fig. 9).  474 
Neutralizing antibody responses were observed predominantly against HIV-1 Tier 1 475 
viruses, with no differences between NYVAC-C and ALVAC-C immunization groups, 476 
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using the TZM.BL neutralization assay (Fig. 9). Similar results were obtained using the 477 
A3R5.7 neutralization assay (data not shown). Of note, immunization with N2NP2 (C) 478 
and A2AP2 (C) performed better neutralization against HIV-1 clade C virus isolates 479 
(strain MW965.26), whereas immunization with A2AP2 (B/E, AIDSVAX) elicited a 480 
better neutralization against HIV-1 clade B virus isolates (MN-3). Moreover, the 481 
kinetics of the neutralization response showed that the higher levels of neutralizing 482 
antibodies and the higher rate of responders were elicited at week 26 in all the 483 
immunization groups. Interestingly, at week 14 immunization with N2NP2 (C) elicited 484 
a higher rate of responders than A2AP2 (C) when analyzing the neutralization against 485 
clade C strain MW965.26 and clade AE strain TH023.6. 486 
In summary, these results showed that immunization with NYVAC-C and ALVAC-C 487 
induced similar levels of neutralizing antibodies against HIV-1, but NYVAC-C induced 488 
a higher rate of responders particularly after a single booster immunization. 489 
 490 
NYVAC-C and ALVAC-C induced low or absent binding IgA antibodies against 491 
HIV-1 gp120 and MuLV gp70-scaffolded V1/V2 proteins 492 
The RV144 phase III clinical trial showed that high levels of binding plasma IgA 493 
antibodies to HIV-1 Env correlated directly with increased risk rate of infection (33, 494 
47). Thus, we next analyzed the binding IgA antibodies elicited after immunization with 495 
N2NP2 (C), A2AP2 (C), A2AP2 (B/E, C) and A2AP2 (B/E, AIDSVAX), quantifying in 496 
individual serum samples obtained from each immunized rhesus monkey at weeks 0 and 497 
26 the total binding IgA antibody levels against HIV-1 gp120 and MuLV gp70-498 
scaffolded V1/V2 proteins (both from clade C) (Fig. 10). Results revealed that 499 
immunization with N2NP2 (C) and A2AP2 (C) induced similar low or absent levels of 500 
binding IgA antibodies against MuLV gp70-scaffolded V1/V2 (Fig. 10A) or HIV-1 501 
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gp120 from isolate 1086 (Fig. 10B). Besides the results presented in Figure 10, we have 502 
also analyzed the IgA binding antibodies against multiple HIV-1 clades: clade C gp120 503 
TV1, and recombinant gp140 consensus from various subtypes (clades A 00MSA4076 504 
and A1.con.env03 gp140, clades B JRFL and B.con.env03 gp140, clade C.con.env03 505 
gp140 and group M consensus). The results with the different gp120/gp140 isolates 506 
showed that no IgA antibodies against the clades A, B, C and group M analysed were 507 
induced in the four immunization groups (data not shown). In summary, these results 508 
showed that immunization with NYVAC-C and ALVAC-C induced very low levels of 509 
binding IgA antibodies against HIV-1 gp120 and specifically MuLV gp70-scaffolded 510 
V1/V2 proteins. 511 
512 
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DISCUSSION 513 
In 2009, the RV144 phase III clinical trial in 16,000 volunteers at risk of infection in 514 
Thailand showed for the first time that an effective HIV/AIDS vaccine could potentially 515 
be developed. Immunization with a combination of a recombinant canarypoxvirus 516 
vector (ALVAC) expressing HIV-1 antigens from clade E (gp120) and clade B 517 
(Gag/Pro) and bivalent HIV-1 gp120 proteins from clades B/E, showed a 31.2% 518 
protection against HIV-1 infection in humans (1). There was limited immunogenicity 519 
for what was experimentally measured (T-cell and antibody responses) and the efficacy 520 
obtained in this clinical trial was considered modest. Nonetheless, this study highlighted 521 
the importance of recombinant poxvirus vectors as components of HIV/AIDS vaccine 522 
candidates.  523 
Several recombinant poxvirus vectors (including MVA, NYVAC, canarypox and 524 
fowlpox) expressing different HIV-1 antigens have been broadly used in several human 525 
clinical trials, proving that they are safe and immunogenic, inducing HIV-1-specific 526 
cellular and humoral immune responses [reviews in (2-4, 48)]. However, improved 527 
immunogens based on optimized poxvirus vectors able to enhance the cellular and 528 
humoral immune responses against HIV-1 antigens are needed. Examples include 529 
enhancing replication capacity of the vector, co-expression of immunomodulators, 530 
heterologous prime/boost approaches and removal of poxviral genes antagonizing host 531 
cell-mediated immune responses [reviews in (2, 5)]. 532 
Here, we asked whether improved poxvirus vector immunogens can be produced that 533 
elicit more broadly reactive T- and B-cell immune responses to HIV-1 antigens. This 534 
was examined using a similar prime/boost immunization regimen as in the RV144 trial 535 
comparing head-to-head in immunized rhesus macaques the T-cellular and humoral 536 
immune responses against HIV-1 antigens triggered by the two poxvirus vectors 537 
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(ALVAC-C and NYVAC-C) expressing identical and optimized clade C trimeric gp140 538 
and Gag-Pol-Nef as Gag-derived VLPs. Furthermore, this was bench-marked by 539 
comparison of the immune responses elicited by both vectors to the same immunogens 540 
and vaccination protocol as in the RV144 trial to define cross-clade responses. 541 
In all immunization groups, HIV-1-specific CD4+ and CD8+ T cells were generated, but 542 
interestingly, compared to ALVAC-C, NYVAC-C significantly enhanced post 543 
immunization the HIV-1-specific CD4+ T-cell immune responses and elicited a trend 544 
toward higher CD8+ T-cell immune responses. Furthermore, NYVAC-C significantly 545 
enhanced the magnitude of HIV-1-specific CD4+ T cells producing IFN-gγ and/or TNF-α 546 
and/or IL-2.  547 
With regard to the humoral immune responses, priming with NYVAC-C resulted in 548 
increased magnitude and frequency of clade C Env-specific binding IgG antibodies, 549 
with a trend toward higher levels after boosting with protein. In addition, peptide 550 
mapping to gp120 indicate that the most frequent linear IgG antibody response to 551 
specific linear epitopes was directed against the V3 loop in all animal groups, with 552 
reactivity also directed against different protein domains including V2, with animals 553 
immunized with NYVAC-C having the highest frequency of antibodies with these 554 
specificities. Comparison of cross-clade binding IgG antibodies against HIV-1 gp140 555 
from clades A, B and group M consensus showed that NYVAC-C induced higher levels 556 
during the priming phase and similar levels after boosting, compared to ALVAC-C. It 557 
should be pointed out that after priming, immunization with NYVAC-C and ALVAC-C 558 
gave better antibody responses to clade B gp140 than the immunization with clade B 559 
immunogens [A2AP2 (B/E, AIDSVAX)]. This could be due to the nature of the 560 
adjuvant, even though both adjuvants (MF59 and Alum) potentially augment the 561 
immune response through a common mechanism inducing a similar pattern of 562 
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phenotypical and chemokine responses in monocytes (49). Furthermore, immunization 563 
with A2AP2 (B/E, AIDSVAX) also induced good cross-clade antibody responses 564 
against clade C HIV-1 gp140, gp120 antigens. Moreover, rectal binding IgG antibody 565 
levels against HIV-1 gp140 group M consensus (sCon), gp120 from isolate 1086, gp120 566 
from isolate TV1 and MuLV gp70-scaffolded V1/V2 proteins induced by the different 567 
immunization groups were comparable. Furthermore, NYVAC-C and ALVAC-C 568 
elicited comparable levels of ADCC responses, of neutralizing antibodies and similar 569 
low levels of binding IgA antibodies. Although out of 8 animals only one showed high 570 
values of IgA against gp70 V1/V2 and clade C gp120 1086 in the N2NP2(C) group, 571 
however this macaque induced low levels of IgA antibodies against clades A, B, C and 572 
group M. Also the group of animals that got the vaccine similar to the RV144 trial had 573 
low IgA antibody responses. These observations clearly showed that these protocols 574 
trigger low IgA responses. The induction by NYVAC-C of a trend toward higher levels 575 
of binding IgG antibodies against HIV-1 gp140, gp120 and MuLV gp70-scaffolded 576 
V1/V2 and low levels of binding IgA antibodies against Env is particularly important 577 
since antibody responses against V1/V2 loops of HIV-1 gp120 correlated with lower 578 
infection risk in RV144, whereas higher plasma levels of Env-specific IgA were 579 
correlated with a lack of protection (33). These improvements in NYVAC-C were likely 580 
attributed to the higher magnitude of HIV-1-specific CD4+ T helper cells induced in the 581 
NYVAC-C immunization group. Thus, the immunological profiles elicited by NYVAC-582 
C and ALVAC-C are compatible with possible protective mechanisms against HIV-1, 583 
including induction of HIV-1-specific CD4+ and CD8+ T-cell immune responses (50-584 
54) and high levels of IgG antibodies directed against HIV-1 gp120 and MuLV gp70-585 
scaffolded V1/V2, together with low levels of IgA antibodies against HIV-1 gp120 and 586 
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MuLV gp70-scaffolded V1/V2 (33).  Challenge studies in non-human primates 587 
immunized with NYVAC-C and ALVAC-C may help define the best-in-class vector. 588 
The differences in the immune responses between the two poxvirus vectors are likely 589 
related to the nature of the pox vector, as the viral genomes of NYVAC and ALVAC 590 
differ in content of immunomodulatory genes, use of promoters or insertion sites of the 591 
HIV genes. In fact, it has been recently described that ALVAC induces distinct cytokine 592 
responses compared to NYVAC in rhesus macaques (55), a difference that can 593 
influence the HIV-1-specific T-cell and humoral immune responses elicited by the 594 
recombinant ALVAC-C versus NYVAC-C. 595 
A head-to-head comparison of NYVAC and ALVAC vectors expressing Gag-Pol-Env 596 
from SIV has been undertaken, but in SIVmac251-infected rhesus macaques treated 597 
with antiretroviral therapy (ART). These findings demonstrated that both vectors were 598 
immunogenic, inducing similar virus-specific CD8+ T-cell responses and comparable 599 
lymphoproliferative responses to the SIV p27 Gag and gp120 Env proteins (56). 600 
However, no Env protein boost and no antibody responses were investigated in the SIV 601 
study. 602 
The NYVAC and ALVAC immunogens used in this investigation are distinct from any 603 
other previous poxvirus vector. The advantage of these vectors is that they express 604 
independently Env and Gag-Pol-Nef and induced potent innate immune responses (26), 605 
reinforcing that a mixture of two vectors could be a better approach over a single virus 606 
vector as was used in the RV144 trial vaccine regimen (ALVAC-vCP1521). Notably, 607 
previous generation of NYVAC-based HIV-1 immunogens were designed to express 608 
both Env and Gag-Pol-Nef from the same viral TK locus, such as NYVAC-C (vP2010), 609 
a NYVAC HIV-1 immunogen expressing HIV-1 gp120 and Gag-Pol-Nef proteins from 610 
clade C 97CN54. This has been tested as an homologous component in a phase I 611 
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clinical trial (EV01) in healthy volunteers demonstrating safety profile and inducing T-612 
cell immune responses against HIV-1 antigens in 50% of the vaccinees, with most of 613 
the responses being Env-specific (24). Furthermore, a DNA-C prime (two plasmid 614 
vectors)/NYVAC-C (vP2010; old single component) boost immunization protocol 615 
tested in a phase I clinical trial (EV02) significantly enhanced the HIV-1-specific T and 616 
B cell immune responses (25), though again with a Env-antigen specific bias that were 617 
polyfunctional and long-lasting (13). In another recent human clinical trial (HVTN078), 618 
NYVAC was used in combination with an Ad5-based HIV vaccine, where it was shown 619 
that NYVAC was a potent boosting component (23). A similar NYVAC-based 620 
HIV/AIDS therapeutic vaccine candidate expressing Env and Gag-Pol-Nef HIV-1 621 
antigens from clade B (NYVAC-B) has been evaluated in HIV-1-infected patients on 622 
antiretroviral therapy in a phase I clinical trial (Theravac-01). In HIV-infected 623 
individuals, this NYVAC immunogen induced broad, polyfunctional HIV-1-specific T-624 
cell responses, triggering both an expansion of pre-existing T-cell immune responses 625 
and the appearance of newly detected HIV-1-specific CD4+ and CD8+ T-cell responses 626 
(14).  627 
Importantly, the novel poxvirus vectors NYVAC-C and ALVAC-C express HIV-1 628 
antigens from clade C, the most broadly distributed HIV-1 subtype, reinforcing the use 629 
of these combined vectors as HIV/AIDS vaccine candidates in those geographical 630 
regions where HIV-1 clade C is most prevalent. 631 
While there are limited markers that might correlate with protection against HIV, it has 632 
been inferred from the RV144 trial and other studies that vaccine efficacy might be 633 
related to the induction of antibodies against the V1/V2 and V3 loops, production of 634 
neutralizing and non-neutralizing antibodies, cross clade responses, ADCC activation 635 
and induction of CD4+ and CD8+ T-cell responses (31, 33, 42-44, 46). From the 636 
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findings described here it is clear that the poxvirus vectors NYVAC and ALVAC 637 
induced responses to all of these vaccine markers. Whether these immune markers 638 
correlate with control of HIV infection and which of the two poxvirus vectors is best in 639 
eliciting protective efficacy remains to be defined.  640 
Overall, this head-to-head comparison in non-human primates has revealed how 641 
NYVAC-C and ALVAC-C elicit a wide spectrum of different T and B cell immune 642 
responses that may be relevant in protection from HIV infection. These results support 643 
the further clinical development of NYVAC as an HIV vaccine candidate. 644 
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FIGURE LEGENDS 899 
Figure 1. Immunization schedule in non-human primates. (A) Immunization groups 900 
included in the AUP513 study modeled after the RV144 trial vaccine regimen. Eight 901 
non-human primates (NHP) (rhesus macaques) were immunized in each group at weeks 902 
0 and 4 with the corresponding poxvirus vectors (NYVAC-C, ALVAC-C or ALVAC-903 
vCP1521) and at weeks 12 and 24 with a combination of poxvirus vector plus a HIV-1 904 
gp120 protein (from clades C or B/E), as detailed in Materials and Methods. 905 
Composition of NYVAC-C, ALVAC-C, ALVAC-vCP1521 and the bivalent HIV-1 906 
34 
 
gp120 protein from clade C or from clades B/E (AIDSVAX) is detailed in Materials and 907 
Methods. The HIV-1 subtypes included in the corresponding poxvirus vectors or in the 908 
HIV-1 gp120 proteins are indicated between brackets. (B) Chronological diagram 909 
showing the immunization schedule and the immunogenicity endpoints used in this 910 
study. At weeks 0, 4, 12 and 24 animals were immunized as detailed in Figure 1A. A 911 
dose of 1 x 108 PFU of each recombinant poxvirus vector (NYVAC-C, ALVAC-C or 912 
ALVAC-vCP1521; 2 x 108 PFU of total virus) and 50 µg of each HIV-1 gp120 protein 913 
(from clades C or B/E; 100 µg of total protein) were used in each immunization. In 914 
groups 1, 2 and 3, gp120 protein boost is composed of a bivalent clade C gp120 protein 915 
containing a mixture of 50 µg of TV1 gp120 plus 50 µg of 1086 gp120, both from clade 916 
C (total amount of 100 µg). In group 4, gp120 protein boost is composed of a bivalent 917 
AIDSVAX gp120 protein containing a mixture of 50 µg of clade B gp120 plus 50 µg of 918 
clade CRF01_AE gp120 (total amount of 100 µg). Bivalent clade C gp120 protein was 919 
administered together with MF59 adjuvant, and bivalent AIDSVAX gp120 protein was 920 
administered together with alum adjuvant. At weeks 0, 6, 14 and 26 (at the beginning of 921 
the study, two weeks after the second, third and fourth immunizations, respectively), 922 
PBMCs and serum samples were obtained from each immunized animal and HIV-1-923 
specific T-cellular and humoral immune responses were analyzed. 924 
 925 
Figure 2. Immunization with NYVAC-C enhances the magnitude of HIV-1-specific 926 
CD4+ T-cell immune responses and induced a trend toward higher HIV-1-specific 927 
CD8+ T-cell immune responses. Total magnitude of HIV-1-specific CD4+ (A) and 928 
CD8+ (B) T-cell responses elicited by the different immunization groups. PBMCs were 929 
collected at weeks 6, 14 and 26 from each rhesus monkey (n=8 per group) immunized 930 
with N2NP2 (C), A2AP2 (C), A2AP2 (B/E, C) and A2AP2 (B/E, AIDSVAX). HIV-1-931 
35 
 
specific CD4+ and CD8+ T-cell immune responses triggered by the different 932 
immunization groups were measured by ICS assay following stimulation of PBMCs 933 
with HIV-1 Env, Gag, Pol and Nef peptide pools. The values represent the sum of the 934 
percentages of T cells producing IFN-gγ and/or TNF-aα and/or IL-2 against 935 
Env+Gag+Pol+Nef peptide pools. Values from unstimulated controls were subtracted in 936 
all cases. Each dot represents the value from each immunized monkey. Box plots 937 
represent the distribution of data values, with the line inside the box indicating the 938 
median value. p value indicates significantly higher response comparing N2NP2 (C) to 939 
A2AP2 (C) at each week (*, p<0.05).  940 
 941 
Figure 3. Immunization with NYVAC-C enhances the magnitude of HIV-1-specific 942 
CD4+ T-cells producing cytokines. Overall magnitude of HIV-1-specific CD4+ T cells 943 
elicited by the different immunization groups and producing any cytokine (IFN-gγ and/or 944 
TNF-aα and/or IL-2) (A), only IFN-gγ (B), only TNF-aα (C) or only IL-2 (D). PBMCs 945 
were collected at weeks 6, 14 and 26 from each rhesus monkey (n=8 per group) 946 
immunized with N2NP2 (C) and A2AP2 (C). HIV-1-specific CD4+ T-cell immune 947 
responses triggered by both immunization groups were measured by ICS assay 948 
following stimulation of PBMCs with HIV-1 Env, Gag, Pol and Nef peptide pools. The 949 
values represent the sum of the percentages of T cells producing IFN-gγ and/or TNF-aα 950 
and/or IL-2 against Env+Gag+Pol+Nef peptide pools (A), or the percentages of T cells 951 
producing IFN-gγ (B) or TNF-aα (C) or IL-2 (D) against Env+Gag+Pol+Nef peptide 952 
pools. Values from unstimulated controls were subtracted in all cases. Each dot 953 
represented the value from each immunized monkey. Each dot represents the value from 954 
each immunized monkey. Box plots represent the distribution of data values, with the 955 
36 
 
line inside the box indicating the median value. p values indicate significantly higher 956 
responses comparing N2NP2 (C) to A2AP2 (C) at each week (*, p<0.05).  957 
 958 
Figure 4. Immunization with NYVAC-C induces a trend toward an increase in the 959 
levels of binding IgG antibodies against clade C HIV-1 gp140, gp120 and MuLV 960 
gp70-scaffolded V1/V2 proteins. Total binding IgG antibody levels against clade C 961 
HIV-1 gp140 consensus (cCon) (A), gp120 from isolate 1086 (B), gp120 from isolate 962 
TV1 (C) and MuLV gp70-scaffolded V1/V2 proteins (D) induced by the different 963 
immunization groups. Individual sera samples were obtained at weeks -1, 6, 14 and 26 964 
from each rhesus monkey (n=8 per group) immunized with N2NP2 (C), A2AP2 (C), 965 
A2AP2 (B/E, C) and A2AP2 (B/E, AIDSVAX). Binding IgG antibodies were measured 966 
by BAMA, as indicated in Materials and Methods. The magnitude of the antibody 967 
response is expressed as AUC from serial dilutions of plasma. Each dot represents the 968 
value from each immunized monkey. p values indicate significantly higher levels 969 
comparing N2NP2 (C) to A2AP2 (C) at each week (*, p<0.05).  970 
 971 
Figure 5. Immunization with NYVAC-C and ALVAC-C induces similar levels of 972 
rectal IgG binding responses. Rectal binding IgG antibody levels against HIV-1 973 
gp140 group M consensus (sCon) (A), gp120 from isolate 1086 (B), gp120 from isolate 974 
TV1 (C) and MuLV gp70-scaffolded V1/V2 proteins (D) induced by the different 975 
immunization groups. Individual sera samples were obtained at weeks -1, 6, 14 and 26 976 
from each rhesus monkey (n=8 per group) immunized with N2NP2 (C), A2AP2 (C), 977 
A2AP2 (B/E, C) and A2AP2 (B/E, AIDSVAX). Rectal binding IgG antibodies were 978 
measured by analyzing the binding magnitude normalize per total rhesus IgG (specific 979 
37 
 
activity), as indicated in Materials and Methods. Each dot represents the value from 980 
each immunized animal.  981 
 982 
Figure 6. Immunization with NYVAC-C and ALVAC-C induces a trend toward 983 
higher levels of cross-clade binding IgG antibodies against HIV-1 gp140 from 984 
clades A, B and group M consensus. Total cross-clade binding IgG antibody levels 985 
against HIV-1 gp140 consensus from clade A (a1Con) (A), clade B (bCon) (B) and 986 
group M consensus (sCon) (C) induced by the different immunization groups. 987 
Individual sera samples were obtained at weeks -1, 6, 14 and 26 from each rhesus 988 
monkey (n=8 per group) immunized with N2NP2 (C), A2AP2 (C), A2AP2 (B/E, C) and 989 
A2AP2 (B/E, AIDSVAX). Binding IgG antibodies were measured by BAMA, as 990 
indicated in Materials and Methods. The magnitude of the antibody response is 991 
expressed as AUC from serial dilutions of plasma. Each dot represents the value from 992 
each immunized monkey. p values indicate significantly higher levels comparing 993 
N2NP2 (C) to A2AP2 (C) at each week (*, p<0.05).  994 
 995 
Figure 7. NYVAC-C and ALVAC-C induces IgG antibodies mainly directed 996 
against the V3 loop. Plasma linear IgG binding epitope specificity against different 997 
linear epitopes covering HIV-1 gp160 of 7 consensus from clades A, B, C, D, group M, 998 
CRF01 and CRF02 in a subset of animals that developed strong binding IgG antibodies. 999 
(A) Percent of total gp160 binding specific for each epitope. % of total gp160 binding is 1000 
defined as: maximum binding to the epitope/sum of maximum binding to all epitopes 1001 
identified. Each slice represents the average percentage values of the 7 animals mapped. 1002 
(B) Binding magnitude to each linear epitope identified. Binding magnitude is shown as 1003 
maximum binding to each epitope: highest binding (signal intensity) to a single peptide 1004 
38 
 
in each epitope region. Region of each epitope identified (shown as the range of 1005 
peptides included in the array library) is listed under the epitope in parentheses.   1006 
 1007 
Figure 8. Immunization with NYVAC-C and ALVAC-C induces similar levels of 1008 
ADCC responses against HIV-1. ADCC activity induced by the different 1009 
immunization groups. Individual plasma samples were obtained at weeks 0 and 26 from 1010 
each rhesus monkey (n=8 per group) immunized with N2NP2 (C), A2AP2 (C), A2AP2 1011 
(B/E, C) and A2AP2 (B/E, AIDSVAX). ADCC activity was measured as indicated in 1012 
Materials and Methods. Each dot represents the value from each immunized monkey. 1013 
Box plots represent the distribution of data values, with the line inside the box 1014 
indicating the median value.   1015 
 1016 
Figure 9. Immunization with NYVAC-C and ALVAC-C induces similar levels of 1017 
neutralizing antibodies against HIV-1. Neutralization titers and percentage of 1018 
responders induced by the different immunization groups. Individual sera samples were 1019 
obtained at weeks -1, 6, 14, 26 from each rhesus monkey (n=8 per group) immunized 1020 
with N2NP2 (C), A2AP2 (C), A2AP2 (B/E, C) and A2AP2 (B/E, AIDSVAX). 1021 
Neutralizing antibodies against clade B tier 1 HIV-1 strain MN.3, clade C tier 1 HIV-1 1022 
strain MW965.26 and clade CRF01_AE tier 1 HIV-1 strain TH023.6 were measured 1023 
using the TZM-bl assay, as indicated in Materials and Methods. Each dot represents the 1024 
value from each immunized monkey. Blue dots indicate non-responders and red dots 1025 
responders. Box plots represent the distribution of data values, with the line inside the 1026 
box indicating the median value. Boxes and whiskers represent positive responders only 1027 
(see Materials and Methods). 1028 
 1029 
39 
 
Figure 10. Immunization with NYVAC-C and ALVAC-C induces low levels of 1030 
binding IgA antibodies against HIV-1 gp120 and MuLV gp70-scaffolded V1/V2 1031 
proteins. Total binding IgA antibody levels against MuLV gp70-scaffolded V1/V2 (A) 1032 
and gp120 from the clade C primary isolate 1086 (B) induced by the different 1033 
immunization groups. Individual sera samples were obtained at weeks 0 and 26 from 1034 
each rhesus monkey (n=8 per group) immunized with N2NP2 (C), A2AP2 (C), A2AP2 1035 
(B/E, C) and A2AP2 (B/E, AIDSVAX). Binding IgA antibodies against MuLV gp70-1036 
scaffolded V1/V2 and gp120 from isolate 1086 were measured by BAMA, as indicated 1037 
in Materials and Methods. The magnitude of the antibody response is expressed as the 1038 
fluorescence intensity background (FI bg)-subtracted at dilution 1/80. Each dot 1039 
represents the value from each immunized monkey. Box plots represent the distribution 1040 
of data values, with the line inside the box indicating the median value.  1041 










